Executive Director, Global Commercial Lead

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$265K-$331K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$93,011 U.S. median for this role

Projected growth (BLS Employment Projections)

+5.1% - Faster than average

220% above the BLS role benchmark for marketing aggregate.

Posted salary is far from this role benchmark; treat it as low confidence.

Matched to SOC 13-1161 - Marketing aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Marketing From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Executive Director, Global Commercial Lead Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, Global Commercial Development Disease Area Lead, this newly created role will serve as a leader for continuing to build our global oncology marketing capabilities driving global commercial strategy at product team and overseeing global launch strategy and lifecycle planning for a given indication/indications. Candidates should be passionate about leading cross-functional collaboration, and contributing as both a strategic leader and hands-on driver in a growing organization. This position is primarily remote with travel required for scientific and team meetings. Specifically, you will be responsible for: - Partner across the company including with clinical development, medical affairs, market access, to drive indication strategy, shape brand strategies across the product team. - Ensure global readiness to drive successful launch planning, commercialization, and performance tracking across the U.S. and key ex-U.S. markets. - Execute global disease area strategy, brand strategies, including branding,

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.